Analytical validation of hepatitis B core‐related antigen (HBcrAg) using dried blood spots (DBS)

Analytical validation of hepatitis B core‐related antigen (HBcrAg) using dried blood spots (DBS)

Limited access to nucleic acid testing (NAT) to quantify HBV DNA levels, an essential tool to determine anti‐HBV treatment eligibility, represents a significant barrier to scale up HBV diagnostic services in resource‐limited countries. Hepatitis B core‐related antigen (HBcrAg) has the potential to b...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of viral hepatitis 2021-05, Vol.28 (5), p.837-843
Hauptverfasser: Shimakawa, Yusuke, Vernoux, Laura, Gabassi, Audrey, Mercier‐Delarue, Séverine, Vincent, Jeanne Perpétue, Simon, François, Maylin, Sarah
Format: Artikel
Sprache:eng
Schlagworte:
analytical validation
Antigens
Antiviral agents
Blood
Centrifugation
Deoxyribonucleic acid
diagnostic test
DNA
dried blood spot
Elution
Enzyme immunoassay
Genotypes
Hepatitis
Hepatitis B
hepatitis B core‐related antigen
Life Sciences
Original
Patients
resource‐limited country
Santé publique et épidémiologie
Viremia
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Limited access to nucleic acid testing (NAT) to quantify HBV DNA levels, an essential tool to determine anti‐HBV treatment eligibility, represents a significant barrier to scale up HBV diagnostic services in resource‐limited countries. Hepatitis B core‐related antigen (HBcrAg) has the potential to become an affordable alternative because of its low cost (US$
ISSN:1352-0504
1365-2893
DOI:10.1111/jvh.13489